within Pharmacolibrary.Drugs.ATC.L;

model L01DB05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0005833333333333334,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.015,
    k12             = 20,
    k21             = 20
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DB05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Zorubicin (also known as 4'-deoxy-doxorubicin) is an anthracycline antitumor antibiotic, structurally related to doxorubicin. It was developed for the treatment of various cancers including bladder cancer, but it is not widely approved or used in modern oncology due to limited adoption and availability.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult cancer patients following intravenous administration, based on structural similarity to doxorubicin and sparse literature data.</p><h4>References</h4><ol><li><p>Jaenke, RS, et al., &amp; Trouet, A (1980). Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. <i>Cancer research</i> 40(10) 3530–3536. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6934026/&quot;>https://pubmed.ncbi.nlm.nih.gov/6934026</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DB05;
